Here's Why You Should Add SMMT Stock to Your Portfolio Now
Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.
SMMT - Summit Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$23.00
LOW:
$16.00
MEDIAN:
$18.00
CONSENSUS:
$19.00
UPSIDE:
14.32%
Stock News
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts.
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summit's executive officers and whether investor losses may be recovered under federal securities laws.
Summit Therapeutics Stock Dips After Q1 Financial Report
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2026. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects ass.
IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?
Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fueled broad gains.
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst
Ivonescimab is a PD-1xVEGF bispecific antibody under development for cancer, primarily for lung cancer.
Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT
Aberdeen Group plc lowered its stake in Summit Therapeutics PLC (NASDAQ: SMMT) by 18.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 927,171 shares of the company's stock after selling 212,359 shares during the period. Aberdeen
Summit Therapeutics (NASDAQ:SMMT) and Cosmos Health (NASDAQ:COSM) Financial Contrast
Summit Therapeutics (NASDAQ: SMMT - Get Free Report) and Cosmos Health (NASDAQ: COSM - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Analyst Ratings This is a summary of current
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and.
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
Citigroup Inc. Acquires 46,535 Shares of Summit Therapeutics PLC $SMMT
Citigroup Inc. increased its holdings in Summit Therapeutics PLC (NASDAQ: SMMT) by 41.1% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 159,873 shares of the company's stock after buying an additional 46,535 shares during the quarter. Citigroup Inc.'s holdings in Summit Therapeutics were worth
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Summit Therapeutics (NASDAQ:SMMT) and Wellgistics Health (NASDAQ:WGRX) Head to Head Comparison
Wellgistics Health (NASDAQ: WGRX - Get Free Report) and Summit Therapeutics (NASDAQ: SMMT - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Profitability This table compares Wellgistics Health and Summit
Summit Therapeutics to Present at Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday.
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
Price Targets
Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright
$23.00
(was $16.11)
H.C. Wainwright
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler
$16.00
(was $21.46)
Piper Sandler
Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
$30.00
(was $16.09)
H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
$40.00
(was $16.89)
Piper Sandler
Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight
$18.00
(was $17.23)
Etzer Darout
·
Summit Redstone Partners
Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright
$40.00
(was $20.04)
H.C. Wainwright
Summit Therapeutics price target raised to $16 from $13 at Barclays
$16.00
(was $20.04)
Barclays
Summit Therapeutics initiated with an Underweight at Barclays
$13.00
(was $18.12)
Summit Redstone Partners
Piper starts Summit Therapeutics with Neutral on high expectations
$21.00
(was $25.71)
Kelsey Goodwin
·
Summit Redstone Partners
Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
$44.00
(was $24.11)
H.C. Wainwright
Wells says Summit, Akeso data 'not the bull case,' but not 'bear case either'
$30.00
(was $23.47)
Wells Fargo
Jefferies uncovers China approval for Summit Therapeutics, ups target
$44.00
(was $25.61)
Kelly Shi
·
Jefferies
Summit Therapeutics upgraded to Buy from Neutral at Citi
$35.00
(was $19.89)
Yigal Nochomovitz
·
Summit Redstone Partners
Goldman starts Summit Therapeutics with a Buy on ivonescimab potential
$42.00
(was $20.69)
Summit Redstone Partners
JMP Securities Starts Summit Therapeutics plc (SMMT) at Market Outperform
$32.00
(was $19.96)
Reni Benjamin
·
JMP Securities
Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
$23.00
(was $20.89)
Yigal Nochomovitz
·
Summit Redstone Partners
Summit Therapeutics plc (SMMT) PT Raised to $40 at Stifel
$40.00
(was $24.00)
Brad Canino
·
Stifel Nicolaus
Summit Therapeutics price target raised to $45 from $30 at H.C. Wainwright
$45.00
(was $31.93)
Mitchell Kapoor
·
H.C. Wainwright
Summit Therapeutics plc (SMMT) PT Raised to $14 at Stifel
$14.00
(was $8.69)
Brad Canino
·
Stifel Nicolaus
Stifel Starts Summit Therapeutics plc (SMMT) at Buy, 'ivonescimab has high probability-of-success'
$8.00
(was $3.28)
Brad Canino
·
Stifel Nicolaus